Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion Upfront
Johnson & Johnson is buying the eye-disease biotech for $2.2 billion upfront, the company said Monday. Ollin's main experimental drug is designed to treat eye diseases that can cause vision loss.
By Alex JaninJohnson & Johnson is buying eye-disease biotech Ollin Biosciences for $2.2 billion upfront, the health-care giant said Monday.Ollin's main experimental drug is designed to treat eye diseases that can cause vision loss. The purchase marks an expansion into eye medicines for J&J, which a…